AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Hematologic disorder

diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tra…

🔔 Follow weekly
🧬7249genes / proteins with evidence
💊301drugs and clinical candidates
🧪12+recruiting trials worldwide
✅10approved
📈1filed for approval
🧬

Understand diffuse large B-cell lymphoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.

From the Open Targets disease record ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for diffuse large B-cell lymphoma itself.

🤖

AI briefing

Where the science on diffuse large B-cell lymphoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens diffuse large B-cell lymphoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
CD79B CD79b moleculePROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.78
MYD88 MYD88 innate immune signal transduction adaptorPROTACantibody🧊 AlphaFold structure ↗ 0.72
CREBBP CREB binding lysine acetyltransferase PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.69
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.69
TBL1XR1 TBL1X/Y related 1PROTAC🧊 AlphaFold structure ↗ 0.67
B2M beta-2-microglobulinPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.67
KMT2D lysine methyltransferase 2DPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.66
P2RY8 P2Y receptor family member 8PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.65
PIM1 Pim-1 proto-oncogene, serine/threonine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.65
TNFAIP3 TNF alpha induced protein 3PROTAC🧊 AlphaFold structure ↗ 0.65
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunitPROTACsmall molecule🧊 AlphaFold structure ↗ 0.64
BTG1 BTG anti-proliferation factor 1🧊 AlphaFold structure ↗ 0.63
TNFRSF14 TNF receptor superfamily member 14antibodysmall molecule🧊 AlphaFold structure ↗ 0.63
CARD11 caspase recruitment domain family member 11PROTACantibody🧊 AlphaFold structure ↗ 0.63
SOCS1 suppressor of cytokine signaling 1🧊 AlphaFold structure ↗ 0.63

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to diffuse large B-cell lymphoma, by how far it has got
Approved · 10
Axicabtagene CiloleucelB-lymphocyte antigen CD19 binding agentApproved
EpcoritamabB-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agentApproved
GlofitamabB-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agentApproved
Lisocabtagene MaraleucelB-lymphocyte antigen CD19 binding agentApproved
Loncastuximab TesirineB-lymphocyte antigen CD19 binding agentApproved
OcrelizumabB-lymphocyte antigen CD20 binding agentApproved
Show all 10
Polatuzumab VedotinB-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhi…Approved
SelinexorExportin-1 inhibitorApproved
TafasitamabB-lymphocyte antigen CD19 binding agentApproved
TisagenlecleucelB-lymphocyte antigen CD19 binding agentApproved
In phase 2 / 3 · 20
RituximabB-lymphocyte antigen CD20 binding agentFiled for approval
AcalabrutinibTyrosine-protein kinase BTK inhibitorPhase 3
AvelumabProgrammed cell death 1 ligand 1 otherPhase 3
AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inh…Phase 3
BendamustinePhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 3
Show all 20
BleomycinPhase 3
Bortezomib26S proteasome inhibitorPhase 3
Brentuximab VedotinTubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agentPhase 3
BusulfanPhase 3
CarboplatinPhase 3
CarmustineGlutathione reductase inhibitorPhase 3
CholecalciferolVitamin D receptor agonistPhase 3
CirmtuzumabInactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitorPhase 3
CisplatinPhase 3
CladribinePhase 3
CyclophosphamidePhase 3
CytarabineDNA polymerase (alpha/delta/epsilon) inhibitorPhase 3
Darbepoetin AlfaErythropoietin receptor agonistPhase 3
DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inh…Phase 3
Early trials · 20
Ab-101Phase 1/2
Abc-294640Sphingosine kinase 2 inhibitorPhase 1/2
AderbasibPhase 1/2
Agatolimod SodiumToll-like receptor 9 agonistPhase 1/2
AldesleukinInterleukin-2 receptor agonistPhase 1/2
AlisertibSerine/threonine-protein kinase Aurora-A inhibitorPhase 1/2
Show all 20
AlvocidibCyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitorPhase 1/2
AvadomidePhase 1/2
BarasertibSerine/threonine-protein kinase Aurora-B inhibitorPhase 1/2
BazlitoranToll-like receptor 8 antagonist; Toll-like receptor 7 antagonistPhase 1/2
BelinostatHistone deacetylase inhibitorPhase 1/2
Carfilzomib26S proteasome inhibitorPhase 1/2
CemiplimabProgrammed cell death protein 1 inhibitorPhase 1/2
DanvatirsenSTAT-3 mRNA 3'UTR antisense inhibitorPhase 1/2
Denileukin DiftitoxElongation factor 2 inhibitor; Interleukin-2 receptor binding agentPhase 1/2
Dexamethasone Phosphoric AcidGlucocorticoid receptor agonistPhase 1/2
Dexamethasone Sodium PhosphateGlucocorticoid receptor agonistPhase 1/2
EnitociclibPhase 1/2
EpacadostatIndoleamine 2,3-dioxygenase inhibitorPhase 1/2
ErzotabartPhase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leuke…NCT05281809 · Phase 2 · 📍 PittsburghStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B…NCT07284433 · Phase 1, Phase 2 · 📍 ChicagoDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)NCT07059650 · Phase 1, Phase 2 · 📍 BeijingThis is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaNCT07121946 · Phase 1 · 📍 DuarteA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT05908409 · Phase 1, Phase 2 · 📍 SantanderA First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients Wit…NCT07044050 · Phase 1 · 📍 MontpellierConstitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasNCT06176690 · Phase 1 · 📍 HoustonIntrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Thera…NCT07763210 · Phase 2 · 📍 NashvilleImpact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st LineNCT04670029 · Phase 3 · 📍 BesançonStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Lar…NCT03936153 · Phase 2 · 📍 BeijingSynKIR-310 for Relapsed/Refractory B-NHLNCT06544265 · Phase 1 · 📍 DenverZanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein ExpressionNCT06005870 · Phase 2 · 📍 Wuhan Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy